Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, Katz J, Rollins Y, Barohn RJ, Jackson CE, Tiryaki E, Lomen-Hoerth C, Armon C, Tandan R, Rudnicki SA, Rezania K, Sufit R, Pestronk A, Novella SP, Heiman-Patterson T, Kasarskis EJ, Pioro EP, Montes J, Arbing R, Vecchio D, Barsdorf A, Mitsumoto H, Levin B; QALS Study Group.

Ann Neurol. 2009 Aug;66(2):235-44. doi: 10.1002/ana.21743.

2.

Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis.

Qureshi M, Shui A, Dibernardo AB, Brown RH Jr, Schoenfeld DA, Cudkowicz ME.

Amyotroph Lateral Scler. 2008 Dec;9(6):369-74. doi: 10.1080/17482960802163614. Review.

PMID:
18608098
3.

Toll-like receptor 3 is a potent negative regulator of axonal growth in mammals.

Cameron JS, Alexopoulou L, Sloane JA, DiBernardo AB, Ma Y, Kosaras B, Flavell R, Strittmatter SM, Volpe J, Sidman R, Vartanian T.

J Neurosci. 2007 Nov 21;27(47):13033-41.

4.

WAVE1 is required for oligodendrocyte morphogenesis and normal CNS myelination.

Kim HJ, DiBernardo AB, Sloane JA, Rasband MN, Solomon D, Kosaras B, Kwak SP, Vartanian TK.

J Neurosci. 2006 May 24;26(21):5849-59.

5.

Translating preclinical insights into effective human trials in ALS.

DiBernardo AB, Cudkowicz ME.

Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):1139-49. Epub 2006 Apr 4. Review.

Supplemental Content

Loading ...
Support Center